Back to Journals » Drug Design, Development and Therapy » Volume 11

Profile of mirabegron in the treatment of overactive bladder: place in therapy

Authors Sharaf A, Hashim H

Received 1 August 2016

Accepted for publication 22 September 2016

Published 20 February 2017 Volume 2017:11 Pages 463—467

DOI https://doi.org/10.2147/DDDT.S101630

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Dr Georgios Panos

Ala’a Sharaf, Hashim Hashim

Female and Functional Urology Unit, Bristol Urological Institute, Bristol, UK

Abstract: Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome. It can be used either on its own or as part of a combination. This drug has been extensively studied, with a good number of Phase II and Phase III trials showing promising outcomes. These studies show that mirabegron is an effective, well-tolerated drug, which could have some adverse effects of concern. In this review, we look at the trials on mirabegron, as well as its pharmacokinetics, mechanism of action, and side effects as documented in the literature.

Keywords: mirabegron, overactive bladder disorder, antimuscarinics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]